[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)

(Neutral)

Form Type

6-K

Filing Explained

The filing links its disclosed information to listed registration statements, without stating an offering, sale, or issuance in the supplied text.

Alterity Therapeutics’s Form 6-K is an interim report by a foreign private issuer and is dated September 16, 2026. It states that the report is incorporated by reference into listed Form S-8 and Form F-3 registration statements.

The disclosed consequence is a registration-document linkage: the filing does not itself state that securities were offered, sold, or issued.

The supplied filing lists Exhibit 99.1 but provides no exhibit text, so the underlying material information and any transaction terms cannot be assessed from this record.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/16/2026 - 06:03 AM Accepted by SEC EDGAR 09/16/2026 - 06:00 AM

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1	Application for quotation of securities - ATH

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.